<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123405</url>
  </required_header>
  <id_info>
    <org_study_id>2018-08-EFT-1</org_study_id>
    <secondary_id>2019-000060-20</secondary_id>
    <nct_id>NCT04123405</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis</brief_title>
  <official_title>Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: a Prospective, Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was conducted as a prospective, randomized, multinational, multicenter,&#xD;
      double-blind study in 4 parallel groups of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was the prospective, randomized, multinational, multicenter, double-blind study in&#xD;
      4 parallel groups of patients.&#xD;
&#xD;
      Patients underwent screening examinations at Visit 1. Patients who met all inclusion/ no&#xD;
      exclusion criteria were randomized at the baseline visit (Day 1) to the double-blind&#xD;
      treatment for a duration of 14 days but in case of delayed final visit (Day 15) the patient&#xD;
      could voluntarily take reserve study medication for a maximum of 3 additional days.&#xD;
&#xD;
      After the end of the double-blind treatment phase, the patients underwent an end-of-treatment&#xD;
      (EOT) examinations on Day 15 (+3).&#xD;
&#xD;
      A follow-up phone call within 7 days after Day 15 (or earlier in case of premature&#xD;
      termination) was performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Actual">April 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Per-Protocol Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action, Full Analysis Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action, Per-Protocol Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Symptom Score (MSS) Development Over the Course of the Study, Full Analysis Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Symptom Score (MSS) Development Over the Course of the Study, Per-protocol Set</measure>
    <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-Nasal Outcome Test (SNOT-22) by Visit, Full Analysis Set</measure>
    <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
    <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-Nasal Outcome Test (SNOT-22) by Visit, Per Protocol Set</measure>
    <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
    <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Full Analysis Set</measure>
    <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
    <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Per Protocol Set</measure>
    <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
    <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders and Non-responders to Treatment, Full Analysis Set</measure>
    <time_frame>Day 4, 7, 10 and 15</time_frame>
    <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders and Non-responders to Treatment, Per-Protocol Set</measure>
    <time_frame>Day 4, 7, 10 and 15</time_frame>
    <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">944</enrollment>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Group A: 600 mg acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: 1200 mg acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: 2400 mg acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylcysteine</intervention_name>
    <description>600 mg tablet</description>
    <arm_group_label>Group A: 600 mg acetylcysteine</arm_group_label>
    <arm_group_label>Group B: 1200 mg acetylcysteine</arm_group_label>
    <arm_group_label>Group C: 2400 mg acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to acetylcysteine</description>
    <arm_group_label>Group A: 600 mg acetylcysteine</arm_group_label>
    <arm_group_label>Group B: 1200 mg acetylcysteine</arm_group_label>
    <arm_group_label>Group D: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged between 14 and 75 years inclusive on the date of consent&#xD;
&#xD;
          2. Diagnosis of acute, uncomplicated rhinosinusitis defined at screening visit 1 and at&#xD;
             Visit 2 as:&#xD;
&#xD;
               1. major symptom score (MSS) assessed by the patient ≥8 and ≤12 points for the&#xD;
                  following: rhinorrhea/ anterior discharge, postnasal drip, nasal congestion,&#xD;
                  headache, and facial pain/pressure, whereupon the nasal congestion is mandatory&#xD;
                  and no more than 3 of the 5 symptoms are rated as severe&#xD;
&#xD;
               2. individual score for facial pain/pressure ≥1 (mild) and ≤2 (moderate)&#xD;
&#xD;
               3. presence of symptoms ≤3 days prior to screening visit&#xD;
&#xD;
          3. For adults (≥18 years): Informed consent to participate in the trial provided in&#xD;
             written form; For adolescents (≥14 - &lt;18 years): own subject informed consent/ assent&#xD;
             to participate in the trial and the informed consent from all parent(s)/ legal&#xD;
             guardian(s) provided in written form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity or intolerance to the active substance or any of the&#xD;
             excipients of the trial medication&#xD;
&#xD;
          2. Patient with history of hereditary fructose intolerance, galactose intolerance,&#xD;
             lactase deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          3. Chronic rhinosinusitis (symptoms lasting longer than 3 months)&#xD;
&#xD;
          4. Subjects who have undergone sinus or nasal surgery for chronic rhinosinusitis in the 6&#xD;
             months prior to screening visit&#xD;
&#xD;
          5. Sinus lavage within 7 days prior to screening visit&#xD;
&#xD;
          6. Odontogenic rhinosinusitis&#xD;
&#xD;
          7. Allergic (perennial or seasonal) rhinitis&#xD;
&#xD;
          8. Bronchial asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
          9. Nasal polyposis or clinically relevant nasal septum deviation&#xD;
&#xD;
         10. Concomitant otitis&#xD;
&#xD;
         11. Intranasal or systemic use of corticosteroids within 30 days prior to screening visit&#xD;
&#xD;
         12. Intranasal or systemic use of antibiotics within 30 days prior to screening visit&#xD;
&#xD;
         13. Use of nasal decongestants within 2 days prior to screening visit&#xD;
&#xD;
         14. Concomitant treatment of common cold-like symptoms within 7 days prior to screening&#xD;
             visit with any of the following:&#xD;
&#xD;
               1. Analgesics&#xD;
&#xD;
               2. Non-steroidal anti-inflammatory drugs&#xD;
&#xD;
               3. Antihistamines&#xD;
&#xD;
         15. Concomitant use of intranasal saline irrigation&#xD;
&#xD;
         16. Use of immunosuppressive agents within 30 days prior to screening visit&#xD;
&#xD;
         17. Immunocompromised state&#xD;
&#xD;
         18. Suspicion for acute bacterial rhinosinusitis (defined as presence of purulence for 3&#xD;
             to 4 days with fever ≥ 38.3°C)&#xD;
&#xD;
         19. Pregnant or breast-feeding female patient&#xD;
&#xD;
         20. Female patient of childbearing potential (not surgically sterilized/hysterectomized or&#xD;
             postmenopausal for at least 1 year) who is not currently using (documented at&#xD;
             screening visit) and not willing to use medically reliable methods of contraception&#xD;
             for the entire trial duration such as oral, injectable or implantable contraceptives,&#xD;
             intrauterine contraceptive devices (IUD), sexual abstinence or vasectomized partner&#xD;
&#xD;
         21. Any other condition of the patient (e.g. serious or unstable medical or psychological&#xD;
             condition, acute psychosis) that in the opinion of the investigator may compromise&#xD;
             evaluation of the trial treatment or may jeopardize patient's safety, compliance or&#xD;
             adherence to protocol requirements&#xD;
&#xD;
         22. Participation in ANY research study involving another investigational medicinal&#xD;
             product (IMP) within 30 days prior to screening visit, or simultaneous participation&#xD;
             in another clinical study or previous participation in present study&#xD;
&#xD;
         23. Suspected alcohol/ drug dependence or abuse (including heavy smoking: ≥ 20 cigarettes&#xD;
             daily)&#xD;
&#xD;
         24. Use of snuff tobacco&#xD;
&#xD;
         25. Legal incapacity and/or other circumstances rendering the patient unable to understand&#xD;
             the nature, scope and possible consequences of the trial&#xD;
&#xD;
         26. Subjects who are known or suspected:&#xD;
&#xD;
               -  not to comply with the trial directives&#xD;
&#xD;
               -  not to be reliable or trustworthy&#xD;
&#xD;
               -  to be a dependent person, e.g. a relative, family member, or member/employee of&#xD;
                  the investigator's or sponsor's staff&#xD;
&#xD;
               -  subject is in custody or submitted to an institution due to a judicial order.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01139</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2012</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2032</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2044</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2051</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>37</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Orhei</city>
        <zip>3005</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119571</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123184</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>142190</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192283</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196158</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <results_first_submitted>October 20, 2021</results_first_submitted>
  <results_first_submitted_qc>October 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2021</results_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute uncomplicated rhinosinusitis, acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04123405/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT04123405/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 42 clinical centers located in Bulgaria, Germany, Moldova and Russia.</recruitment_details>
      <pre_assignment_details>Participants were randomized in 1:1:1:1 ratio</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: 600 mg Acetylcysteine</title>
          <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Group B: 1200 mg Acetylcysteine</title>
          <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="P3">
          <title>Group C: 2400 mg Acetylcysteine</title>
          <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="P4">
          <title>Group D: Placebo</title>
          <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol Set</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="212"/>
                <participants group_id="P4" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="235"/>
                <participants group_id="P4" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Contact to subject lost</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>screening failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: 600 mg Acetylcysteine</title>
          <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="B2">
          <title>Group B: 1200 mg Acetylcysteine</title>
          <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Group C: 2400 mg Acetylcysteine</title>
          <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="B4">
          <title>Group D: Placebo</title>
          <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="235"/>
            <count group_id="B2" value="238"/>
            <count group_id="B3" value="238"/>
            <count group_id="B4" value="233"/>
            <count group_id="B5" value="944"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="13.8"/>
                    <measurement group_id="B2" value="40.7" spread="13.6"/>
                    <measurement group_id="B3" value="41.3" spread="13.1"/>
                    <measurement group_id="B4" value="41.1" spread="14.0"/>
                    <measurement group_id="B5" value="41.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="556"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="232"/>
                    <measurement group_id="B4" value="231"/>
                    <measurement group_id="B5" value="928"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set</title>
        <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set</title>
          <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8213" spread="1.98247"/>
                    <measurement group_id="O2" value="-4.7394" spread="1.99090"/>
                    <measurement group_id="O3" value="-4.7758" spread="1.96938"/>
                    <measurement group_id="O4" value="-5.0180" spread="1.98262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Per-Protocol Set</title>
        <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Per-Protocol Set</title>
          <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9085" spread="1.92431"/>
                    <measurement group_id="O2" value="-4.8688" spread="1.84448"/>
                    <measurement group_id="O3" value="-4.8002" spread="1.90569"/>
                    <measurement group_id="O4" value="-5.1256" spread="1.95072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action, Full Analysis Set</title>
        <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action, Full Analysis Set</title>
          <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                    <measurement group_id="O2" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                    <measurement group_id="O3" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action, Per-Protocol Set</title>
        <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action, Per-Protocol Set</title>
          <description>Time to onset of action was defined as first day of active treatment on which MSS showed statistically significant (p value&lt;0.05) improvement from placebo.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                    <measurement group_id="O2" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                    <measurement group_id="O3" value="NA">There was no statistically significant improvement of the drug from placebo on any day</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Symptom Score (MSS) Development Over the Course of the Study, Full Analysis Set</title>
        <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Major Symptom Score (MSS) Development Over the Course of the Study, Full Analysis Set</title>
          <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.634" spread="1.1181"/>
                    <measurement group_id="O2" value="9.640" spread="1.0647"/>
                    <measurement group_id="O3" value="9.702" spread="1.0101"/>
                    <measurement group_id="O4" value="9.683" spread="1.0652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.021" spread="2.0348"/>
                    <measurement group_id="O2" value="9.004" spread="1.9883"/>
                    <measurement group_id="O3" value="9.038" spread="2.1235"/>
                    <measurement group_id="O4" value="9.074" spread="1.9866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.485" spread="2.3376"/>
                    <measurement group_id="O2" value="8.513" spread="2.2303"/>
                    <measurement group_id="O3" value="8.416" spread="2.4390"/>
                    <measurement group_id="O4" value="8.609" spread="2.1298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.821" spread="2.4482"/>
                    <measurement group_id="O2" value="7.695" spread="2.5130"/>
                    <measurement group_id="O3" value="7.723" spread="2.7156"/>
                    <measurement group_id="O4" value="7.761" spread="2.5058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.983" spread="2.7284"/>
                    <measurement group_id="O2" value="6.979" spread="2.5706"/>
                    <measurement group_id="O3" value="7.013" spread="2.7490"/>
                    <measurement group_id="O4" value="6.917" spread="2.6312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.323" spread="2.7807"/>
                    <measurement group_id="O2" value="6.203" spread="2.8719"/>
                    <measurement group_id="O3" value="6.315" spread="2.7980"/>
                    <measurement group_id="O4" value="6.039" spread="2.7838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.528" spread="2.9747"/>
                    <measurement group_id="O2" value="5.538" spread="2.7449"/>
                    <measurement group_id="O3" value="5.576" spread="2.8508"/>
                    <measurement group_id="O4" value="5.126" spread="2.7096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.766" spread="2.8631"/>
                    <measurement group_id="O2" value="4.750" spread="2.6755"/>
                    <measurement group_id="O3" value="4.891" spread="2.7598"/>
                    <measurement group_id="O4" value="4.387" spread="2.6004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.204" spread="2.8149"/>
                    <measurement group_id="O2" value="4.322" spread="2.7254"/>
                    <measurement group_id="O3" value="4.445" spread="2.7381"/>
                    <measurement group_id="O4" value="3.839" spread="2.5924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.634" spread="2.6815"/>
                    <measurement group_id="O2" value="3.763" spread="2.6391"/>
                    <measurement group_id="O3" value="3.845" spread="2.6634"/>
                    <measurement group_id="O4" value="3.404" spread="2.6805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.051" spread="2.5229"/>
                    <measurement group_id="O2" value="3.284" spread="2.6658"/>
                    <measurement group_id="O3" value="3.256" spread="2.5716"/>
                    <measurement group_id="O4" value="2.843" spread="2.6469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.609" spread="2.5200"/>
                    <measurement group_id="O2" value="2.754" spread="2.5680"/>
                    <measurement group_id="O3" value="2.756" spread="2.3795"/>
                    <measurement group_id="O4" value="2.413" spread="2.5608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.038" spread="2.4202"/>
                    <measurement group_id="O2" value="2.246" spread="2.5296"/>
                    <measurement group_id="O3" value="2.218" spread="2.4293"/>
                    <measurement group_id="O4" value="1.943" spread="2.4174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.583" spread="2.3289"/>
                    <measurement group_id="O2" value="1.941" spread="2.5375"/>
                    <measurement group_id="O3" value="1.836" spread="2.3300"/>
                    <measurement group_id="O4" value="1.596" spread="2.3637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.332" spread="2.1485"/>
                    <measurement group_id="O2" value="1.614" spread="2.4459"/>
                    <measurement group_id="O3" value="1.634" spread="2.3178"/>
                    <measurement group_id="O4" value="1.352" spread="2.1882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Symptom Score (MSS) Development Over the Course of the Study, Per-protocol Set</title>
        <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
        <time_frame>Baseline (Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Major Symptom Score (MSS) Development Over the Course of the Study, Per-protocol Set</title>
          <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure). The patient rated the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The MSS is then the sum of single ratings with a possible range from 0 to 15.&#xD;
Mean change from baseline in the daily Major Symptom Score (MSS) over the entire treatment period was calculated as the average total score from Day 2 to 15 compared to Baseline (Day 1). Negative change from baseline means improvement.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.657" spread="1.1201"/>
                    <measurement group_id="O2" value="9.628" spread="1.0595"/>
                    <measurement group_id="O3" value="9.698" spread="1.0319"/>
                    <measurement group_id="O4" value="9.676" spread="1.0823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.080" spread="2.0160"/>
                    <measurement group_id="O2" value="8.935" spread="2.0268"/>
                    <measurement group_id="O3" value="9.127" spread="2.0089"/>
                    <measurement group_id="O4" value="9.068" spread="2.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.545" spread="2.2890"/>
                    <measurement group_id="O2" value="8.395" spread="2.2583"/>
                    <measurement group_id="O3" value="8.528" spread="2.2591"/>
                    <measurement group_id="O4" value="8.594" spread="2.1921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.803" spread="2.4779"/>
                    <measurement group_id="O2" value="7.577" spread="2.5472"/>
                    <measurement group_id="O3" value="7.816" spread="2.5849"/>
                    <measurement group_id="O4" value="7.739" spread="2.5750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.962" spread="2.7401"/>
                    <measurement group_id="O2" value="6.874" spread="2.5865"/>
                    <measurement group_id="O3" value="7.061" spread="2.6522"/>
                    <measurement group_id="O4" value="6.821" spread="2.6717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.315" spread="2.7914"/>
                    <measurement group_id="O2" value="6.093" spread="2.8809"/>
                    <measurement group_id="O3" value="6.349" spread="2.7000"/>
                    <measurement group_id="O4" value="5.937" spread="2.8354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.479" spread="2.9550"/>
                    <measurement group_id="O2" value="5.400" spread="2.7151"/>
                    <measurement group_id="O3" value="5.604" spread="2.7800"/>
                    <measurement group_id="O4" value="4.981" spread="2.7163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.685" spread="2.8250"/>
                    <measurement group_id="O2" value="4.605" spread="2.6399"/>
                    <measurement group_id="O3" value="4.892" spread="2.7421"/>
                    <measurement group_id="O4" value="4.237" spread="2.5914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.117" spread="2.7558"/>
                    <measurement group_id="O2" value="4.181" spread="2.6773"/>
                    <measurement group_id="O3" value="4.382" spread="2.6734"/>
                    <measurement group_id="O4" value="3.652" spread="2.5495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.521" spread="2.6127"/>
                    <measurement group_id="O2" value="3.628" spread="2.5174"/>
                    <measurement group_id="O3" value="3.741" spread="2.5507"/>
                    <measurement group_id="O4" value="3.222" spread="2.6197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.934" spread="2.4039"/>
                    <measurement group_id="O2" value="3.144" spread="2.5214"/>
                    <measurement group_id="O3" value="3.146" spread="2.4538"/>
                    <measurement group_id="O4" value="2.705" spread="2.6042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.493" spread="2.3485"/>
                    <measurement group_id="O2" value="2.572" spread="2.3785"/>
                    <measurement group_id="O3" value="2.608" spread="2.2228"/>
                    <measurement group_id="O4" value="2.300" spread="2.4902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.897" spread="2.2146"/>
                    <measurement group_id="O2" value="2.065" spread="2.2949"/>
                    <measurement group_id="O3" value="2.085" spread="2.2013"/>
                    <measurement group_id="O4" value="1.816" spread="2.3077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.432" spread="2.0812"/>
                    <measurement group_id="O2" value="1.749" spread="2.2779"/>
                    <measurement group_id="O3" value="1.708" spread="2.1128"/>
                    <measurement group_id="O4" value="1.444" spread="2.2198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.221" spread="1.9530"/>
                    <measurement group_id="O2" value="1.409" spread="2.1312"/>
                    <measurement group_id="O3" value="1.524" spread="2.0846"/>
                    <measurement group_id="O4" value="1.193" spread="1.9636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sino-Nasal Outcome Test (SNOT-22) by Visit, Full Analysis Set</title>
        <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
        <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test (SNOT-22) by Visit, Full Analysis Set</title>
          <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="212"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="16.89"/>
                    <measurement group_id="O2" value="36.3" spread="15.82"/>
                    <measurement group_id="O3" value="36.7" spread="16.21"/>
                    <measurement group_id="O4" value="36.3" spread="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="215"/>
                    <count group_id="O4" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="15.01"/>
                    <measurement group_id="O2" value="21.2" spread="13.14"/>
                    <measurement group_id="O3" value="22.3" spread="13.95"/>
                    <measurement group_id="O4" value="21.1" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="216"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="10.80"/>
                    <measurement group_id="O2" value="6.9" spread="11.15"/>
                    <measurement group_id="O3" value="7.0" spread="10.07"/>
                    <measurement group_id="O4" value="6.5" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sino-Nasal Outcome Test (SNOT-22) by Visit, Per Protocol Set</title>
        <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
        <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test (SNOT-22) by Visit, Per Protocol Set</title>
          <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="16.64"/>
                    <measurement group_id="O2" value="36.7" spread="15.89"/>
                    <measurement group_id="O3" value="36.4" spread="15.86"/>
                    <measurement group_id="O4" value="36.2" spread="16.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="196"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="14.92"/>
                    <measurement group_id="O2" value="21.2" spread="13.32"/>
                    <measurement group_id="O3" value="22.2" spread="14.27"/>
                    <measurement group_id="O4" value="21.0" spread="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="198"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="10.49"/>
                    <measurement group_id="O2" value="7.1" spread="11.43"/>
                    <measurement group_id="O3" value="6.8" spread="9.67"/>
                    <measurement group_id="O4" value="6.6" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Full Analysis Set</title>
        <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
        <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Full Analysis Set</title>
          <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.8" spread="33.25"/>
                    <measurement group_id="O2" value="-38.2" spread="37.48"/>
                    <measurement group_id="O3" value="-36.7" spread="34.61"/>
                    <measurement group_id="O4" value="-39.6" spread="30.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="209"/>
                    <count group_id="O3" value="209"/>
                    <count group_id="O4" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.3" spread="31.27"/>
                    <measurement group_id="O2" value="-78.9" spread="31.11"/>
                    <measurement group_id="O3" value="-78.6" spread="30.53"/>
                    <measurement group_id="O4" value="-81.5" spread="26.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Per Protocol Set</title>
        <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
        <time_frame>Baseline (Day 1), Day 7 and Day 14</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Per Protocol Set</title>
          <description>SNOT-22 Questionnaire is a disease specific Health-Related Quality of Life (HRQoL) measure that comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant is asked to rate how severe each problem had been on a scale from 0 (no problem) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating better HRQoL. A negative change from baseline in SNOT-22 is considered a favorable outcome.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.4" spread="32.64"/>
                    <measurement group_id="O2" value="-39.5" spread="36.68"/>
                    <measurement group_id="O3" value="-36.7" spread="33.44"/>
                    <measurement group_id="O4" value="-39.6" spread="30.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="196"/>
                    <count group_id="O3" value="192"/>
                    <count group_id="O4" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.8" spread="30.90"/>
                    <measurement group_id="O2" value="-78.6" spread="31.77"/>
                    <measurement group_id="O3" value="-79.1" spread="30.16"/>
                    <measurement group_id="O4" value="-81.0" spread="27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders and Non-responders to Treatment, Full Analysis Set</title>
        <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
        <time_frame>Day 4, 7, 10 and 15</time_frame>
        <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders and Non-responders to Treatment, Full Analysis Set</title>
          <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
          <population>Full-Analysis Set (FAS) included all randomized patients who received at least one dose of the trial medication and who had at least one post-baseline assessment of MSS during the double-blind treatment period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="235"/>
                    <count group_id="O3" value="237"/>
                    <count group_id="O4" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="151"/>
                    <measurement group_id="O4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="235"/>
                    <count group_id="O3" value="227"/>
                    <count group_id="O4" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="212"/>
                    <measurement group_id="O4" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="235"/>
                    <count group_id="O4" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="225"/>
                    <measurement group_id="O3" value="230"/>
                    <measurement group_id="O4" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="238"/>
                    <count group_id="O4" value="228"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="230"/>
                    <measurement group_id="O4" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders and Non-responders to Treatment, Per-Protocol Set</title>
        <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
        <time_frame>Day 4, 7, 10 and 15</time_frame>
        <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: 600 mg Acetylcysteine</title>
            <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1200 mg Acetylcysteine</title>
            <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O3">
            <title>Group C: 2400 mg Acetylcysteine</title>
            <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
          <group group_id="O4">
            <title>Group D: Placebo</title>
            <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders and Non-responders to Treatment, Per-Protocol Set</title>
          <description>Number of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator were reported.</description>
          <population>Per-Protocol Set (PPS) included all FAS-evaluable patients who completed the double-blind treatment period without major protocol violations that could affect the efficacy evaluation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="191"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="209"/>
                    <measurement group_id="O4" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="206"/>
                    <measurement group_id="O4" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment up to maximum duration of 22 days.</time_frame>
      <desc>Any signs or symptoms were collected from first dose of study treatment up to maximum duration of 22 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: 600 mg Acetylcysteine</title>
          <description>one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="E2">
          <title>Group B: 1200 mg Acetylcysteine</title>
          <description>two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="E3">
          <title>Group C: 2400 mg Acetylcysteine</title>
          <description>four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)</description>
        </group>
        <group group_id="E4">
          <title>Group D: Placebo</title>
          <description>four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Otitis media bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Human chorionic gonadotropin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nasal crusting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

